Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 8,839 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety and Tolerability, Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers

NCT05592951
View directory record Official record
Conditions
Safety, Tolerance
Interventions
Crystal Light (once serving), Liquid IV with amino acids (one serving), Liquid IV with amino acids (two servings), Liquid IV with amino acids (three servings)
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 5, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure

NCT04157751
View directory record Official record
Conditions
Heart Failure
Interventions
Empagliflozin, Placebo to Empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
30
States / cities
Los Angeles, California • Orange, California • Torrance, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 5, 2026, 5:43 PM EDT
Completed Phase 1 Interventional

A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis

NCT04090229
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ASLAN004, ASLAN004 Placebo
Drug
Lead sponsor
ASLAN Pharmaceuticals
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Fremont, California • Los Angeles, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 5, 2026, 5:43 PM EDT
Recruiting Phase 1 Interventional

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

NCT06343402
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C, Metastatic Lung Cancer, Advanced Lung Carcinoma
Interventions
BBO-8520, Pembrolizumab, BBO-10203
Drug
Lead sponsor
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
23
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 5, 2026, 5:43 PM EDT
Terminated Phase 1 Interventional

A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction

NCT04855201
View directory record Official record
Conditions
Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
Interventions
Bocidelpar, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 5, 2026, 5:43 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic, Safety and Tolerability Study of SPARC1028

NCT01305512
View directory record Official record
Conditions
Solid Tumor in Advanced Stage
Interventions
SPARC1028
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 5, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery

NCT00718081
View directory record Official record
Conditions
Major Upper or Lower Abdominal Surgery
Interventions
Oral sufentanil, Placebo
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2015 · Synced Oct 5, 2026, 5:43 PM EDT
Completed Phase 1 Interventional

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

NCT04666129
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer
Interventions
Relugolix, Abiraterone, Prednisone, Methylprednisolone, Apalutamide, Docetaxel
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 5, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults

NCT03201419
View directory record Official record
Conditions
Nocturia
Interventions
FE 201836, Desmopressin, Placebo oral solution, Placebo ODT
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Mobile, Alabama • Lincoln, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 5, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Tolerability, and Safety of DFN-15

NCT03009019
View directory record Official record
Conditions
Migraine Headache
Interventions
DFN-15 Active, DFN-15 Placebo
Drug · Other
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 75 Years
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 5, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).

NCT03713619
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
18
States / cities
Birmingham, Alabama • Rogers, Arkansas • Anaheim, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 5, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet

NCT02108639
View directory record Official record
Conditions
Hepatitis C
Interventions
DCV 3DAA FDC, BMS-791325
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Oct 5, 2026, 5:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant

NCT03380377
View directory record Official record
Conditions
Antibody-mediated Rejection, Kidney Transplant; Complications, Transplant Glomerulopathy, Transplant Glomerulopathy - Late Form, Transplant Glomerulopathy - Early Form, Kidney Transplant Rejection
Interventions
Clazakizumab
Drug
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
15 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 5, 2026, 5:43 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

NCT00827177
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Treatment with ARQ 197 in combination with sorafenib
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts • Buffalo, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 5, 2026, 5:43 PM EDT
Recruiting Phase 3 Interventional

A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as an Additional Treatment in Participants With Generalized Anxiety Disorder (GAD)

NCT07807865
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
ITI-1284
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Los Angeles, California • Miami, Florida • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 5, 2026, 5:43 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration

NCT04984707
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
KX0826, Placebo
Drug · Other
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 5, 2026, 5:43 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis

NCT05064436
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
11C-BMS-986196
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 5, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

NCT04233879
View directory record Official record
Conditions
HIV-1 Infection
Interventions
DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 5, 2026, 5:43 PM EDT
Not listed Phase 1 Interventional

Single-Blind Study of STAT-205 in Mild COVID-19

NCT04708327
View directory record Official record
Conditions
COVID-19
Interventions
STAT-205
Drug
Lead sponsor
Cytocom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Loma Linda, California • Pompano Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Oct 5, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of KBP-7072

NCT02454361
View directory record Official record
Conditions
Healthy
Interventions
KBP-7072, Placebo
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 45 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 5, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers

NCT02382666
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 5, 2026, 5:43 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas

NCT01284231
View directory record Official record
Conditions
Gastrointestinal Adenocarcinomas
Interventions
MEDI-565
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Augusta, Georgia • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Oct 5, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability of KBP-5074 Tablet vs Capsule Formulations

NCT03340753
View directory record Official record
Conditions
Bioequivalence
Interventions
KBP-5074 Capsule, KBP-5074 Tablet
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 5, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)

NCT05176639
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Veligrotug, Placebo
Drug
Lead sponsor
Viridian Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
29
States / cities
Aurora, California • Beverly Hills, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 5, 2026, 5:43 PM EDT